Krag A, Israelsen H, Ryberg BV, Andersen KK, Bendtsen F. Safety and efficacy of Profermin® to induce remission in ulcerative colitis. World J Gastroenterol 2012; 18(15): 1773-1780 [PMID: 22553401 DOI: 10.3748/wjg.v18.i15.1773]
Corresponding Author of This Article
Aleksander Krag, MD, PhD, Gastrounit, Medical Devision 360, Copenhagen University Hospital Hvidovre, Faculty of Health Sciences, Copenhagen University, Kettegaard Alle 30, DK-2650 Hvidovre, Denmark. aleksanderkrag@hotmail.com
Article-Type of This Article
Brief Article
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Krag A, Israelsen H, Ryberg BV, Andersen KK, Bendtsen F. Safety and efficacy of Profermin® to induce remission in ulcerative colitis. World J Gastroenterol 2012; 18(15): 1773-1780 [PMID: 22553401 DOI: 10.3748/wjg.v18.i15.1773]
World J Gastroenterol. Apr 21, 2012; 18(15): 1773-1780 Published online Apr 21, 2012. doi: 10.3748/wjg.v18.i15.1773
Safety and efficacy of Profermin® to induce remission in ulcerative colitis
Aleksander Krag, Hans Israelsen, Bjørn von Ryberg, Klaus K Andersen, Flemming Bendtsen
Aleksander Krag, Flemming Bendtsen, Gastrounit, Medical Devision 360, Copenhagen University Hospital Hvidovre, Faculty of Health Sciences, Copenhagen University, DK-2650 Hvidovre, Denmark
Hans Israelsen, Bjørn von Ryberg, Nordisk Rebalance A/S, M. D. Madsensvej 14-16, DK-3450 Allerød, Denmark
Klaus K Andersen, Statistics Section, Informatics and Mathematical Modelling, Technical University of Denmark, DK-2800 Lyngby, Denmark
Author contributions: Israelsen H, von Ryberg B and Andersen KK conceived the study and developed the overall design; Israelsen H and von Ryberg B performed the study; Andersen KK performed the statistical analyses and all authors participated in the interpretation of the overall results; all authors had full access to all data; Krag A drafted the paper and all authors participated in the critical revision for important intellectual content.
Supported by Danish Innovation Law Grant, J.nr. 3414-06-01530, from the Danish Food Industry Agency under the Ministry of Food, Agriculture and Fisheries; and Nordisk Rebalance, who developed and manufactured Profermin®, and partly financed the study
Correspondence to: Aleksander Krag, MD, PhD, Gastrounit, Medical Devision 360, Copenhagen University Hospital Hvidovre, Faculty of Health Sciences, Copenhagen University, Kettegaard Alle 30, DK-2650 Hvidovre, Denmark. aleksanderkrag@hotmail.com
Telephone: +45-3-8623182 Fax: +45-3-8623777
Received: August 15, 2011 Revised: October 23, 2011 Accepted: January 18, 2012 Published online: April 21, 2012
Abstract
AIM: To test the efficacy and safety of Profermin® in inducing remission in patients with active ulcerative colitis (UC).
METHODS: The study included 39 patients with mild to moderate UC defined as a Simple Clinical Colitis Activity Index (SCCAI) > 4 and < 12 (median: 7.5), who were treated open-label with Profermin® twice daily for 24 wk. Daily SCCAI was reported observer blinded via the Internet.
RESULTS: In an intention to treat (ITT) analysis, the mean reduction in SCCAI score was 56.5%. Of the 39 patients, 24 (62%) reached the primary endpoint, which was proportion of patients with ≥ 50% reduction in SCCAI. Our secondary endpoint, the proportion of patients in remission defined as SCCAI ≤ 2.5, was in ITT analysis reached in 18 of the 39 patients (46%). In a repeated-measure regression analysis, the estimated mean reduction in score was 5.0 points (95% CI: 4.1-5.9, P < 0.001) and the estimated mean time taken to obtain half the reduction in score was 28 d (95% CI: 26-30). There were no serious adverse events (AEs) or withdrawals due to AEs. Profermin® was generally well tolerated.
CONCLUSION: Profermin® is safe and may be effective in inducing remission of active UC.
